Press release from Acarix AB (publ) 2017-05-24
Acarix publishes the Interim Report for the period January – March 2017
Today, Wednesday May 24, Acarix is publishing its interim report for the period January – March on the company website www.acarix.com.
The interim report is also attached to this press release.
The first quarter of 2017 was a busy time for Acarix due to preparations for the commercialization of CADScor®System. We continued to pursue our strategy aimed at gradually increasing awareness of the company internationally and we were able to benefit from the interest generated by the company's listing on Nasdaq First North Premier."
Summary of CEO SØREN RYSHOLT CHRISTIANSEN'S comments on the report.
For further information please contact:
Søren Rysholt Christiansen, CEO, E-mail: dksrc@acarix.com Phone: +45 2777 1112
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 24 May 2017.
Notes to editors:
Acarix , CADScor®System and cardiac sound measurement
Acarix A/S was established in 2009, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction in December 2016. Acarix has attracted a highly-experienced management team who have held senior positions in international medical device companies – CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.
Acarix's CADScor®System is based on engineering excellence in sound recording and signal processing. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.
The CADScor®System rules out Coronary Artery Disease with 97% negative predictive value, i.e. a very high diagnostic accuracy. Acarix believes this opens the possibility of use as a frontline test, reducing patient anxiety and waiting times, as well as improving triage for patients needing more expensive and invasive diagnostic modalities.
The Acarix CADScor®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD-score, on the device screen.
The CADScor®System contains the necessary electronics to instruct professionals during use and to guide through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the CADScor® sensor to a fixed position above the heart during the recording.
The software embedded in the Acarix CADScor®System ensures that adequate recording conditions are controlled at every examination.
The CADScor®System is CE Marked (by TÜV in 2015) and due for commercial launch in 2017.
See more at www.acarix.com
Press release_Acarix AB_Interim Report_Q1
Acarix Interim Report Q1 2017l
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
